||JIB-04 (NSC 693627)(E)
||JIB-04 is a pan-selective Jumonji histone demethylase inhibitor.
||SP2509 is a specific histone demethylase LSD1 inhibitor(IC50 =13 nM).
||GSK-LSD1 dihydrochloride(GSK-LSD1 2HCl)
||GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
||GSK-J4 is a potent H3K27me3 demethylase inhibitor, with IC50s of 8.6 µM and 6.6 µM towards KDM6B and KDM6A respectively. It is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the J
||CPI-455 is a specific KDM5 inhibitor.
||GSK2879552 is a selective, orally bioavailable, irreversible, mechanism-based inactivator of lysine-specific demethylase 1 (LSD1)/corepressor, with potential antineoplastic activity.
||Daminozide is a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily.
||KDM4D-IN-1 is a KDM4D inhibitor (IC50: 0.41±0.03 μM).
||OG-L002 is an effective and selective LSD1 inhibitor (IC50: 20 nM), showing 69- and 36-fold selectivity over MAO-A and MAO-B, respectively.
||IOX1 is the most effective broad-spectrum 2OG oxygenases(including the JmjC demethylases) inhibitor. The IC50 of IOX1 for KDM4A, KDM3A, is 0.6 and 0.1 uM, respectively.
||ML324(IC50=920 nM) is a specific inhibitor of jumonji histone demethylase (JMJD2).
||GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.
||ORY-1001 (RG-6016) is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor，with high selectivity against related FAD dependent aminoxidases with IC50 of <20 nM.
||GSK2879552 2HCl (1401966-69-5(free base))
||GSK2879552 is an orally available, irreversible inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
||GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family.